Johnson & Johnson says it can produce 20M doses of COVID-19 vaccine by late March


Johnson & Johnson said Tuesday it can produce 20 million doses of the single-shot coronavirus vaccine by late March and has applied for emergency authorization by the Food and Drug Administration. 


“Assuming necessary regulatory approvals relating to our manufacturing processes, our plan is to begin shipping immediately upon emergency use authorization, and deliver enough single-doses by the end of March to enable the vaccination of more than 20 million Americans,” Richard Nettles, vice president of medical affairs for Johnson & Johnson’s pharmaceutical unit Janssen, told the House Energy and Commerce subcommittee. Nettles’ remarks were published ahead of the meeting.

The panel of lawmakers began hearing testimony from the five companies with contracts to supply COVID-19 shots to the U.S. — Pfizer, Moderna, Johnson & Johnson, AstraZeneca and Novavax– as the supply of vaccines remains short when compared to the increased demand for the coveted shots.

A Phase 3 trial of the Johnson & Johnson vaccine found that the effectiveness of its shot to combat moderate to severe COVID-19 infections was 72% in the United States, 66% in Latin America and 57% in South Africa, 28 days post-vaccination, according to the pharmaceutical company…

Want to know more click here go to source.

From -
Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages

Site Language

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.